Detalles de la búsqueda
1.
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
Blood
; 142(13): 1131-1142, 2023 09 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37363833
2.
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Lancet Oncol
; 23(6): 818-828, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35654052
3.
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.
Haematologica
; 104(1): 147-154, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30115656
4.
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Blood
; 137(8): 1117-1120, 2021 02 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33027809
5.
Multicenter study to evaluate a new enumeration method for hematopoietic stem cell collection management.
Transfusion
; 57(8): 1949-1955, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28653370
6.
Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression.
Leuk Lymphoma
; 63(5): 1070-1079, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34961399
7.
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Lancet Haematol
; 9(3): e190-e199, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35240075
8.
Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
Leuk Lymphoma
; 61(14): 3422-3431, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32865439
9.
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.
Exp Hematol
; 89: 55-60.e6, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32781097
10.
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.
Blood Adv
; 3(17): 2642-2652, 2019 09 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31506282
11.
Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
Blood Adv
; 2(24): 3566-3571, 2018 12 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-30552161
Resultados
1 -
11
de 11
1
Próxima >
>>